CT-202

· Context Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CT-202, covering 2026-04-22 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers [Phase 1]

See pricing